The company will hold off on making a regulatory decision until it sees results from another trial testing the drug with ...

The registrational trial of AD04 could launch as early as mid-2026, if the company is able to shore up necessary funds or ...

RemeGen's disitamab vedotin with Junshi Pharma's Loqtorzi beat standard chemotherapy in first-line HER2-expressing metastatic urothelial cancer.

NEW YORK – Taysha Gene Therapies has regained full rights to its lead program, TSHA-102, for Rett syndrome after an option agreement with Astellas expired.

The new funds will allow the company to test its multi-node PI3K treatment approach in a new endometrial cancer trial.

In a Phase III trial, sacituzumab tirumotecan outperformed chemo in previously treated EGFR-mutant NSCLC patients, results presented at the ESMO Congress show.